Dataset Information
Crizotinib resistance overcome by ceritinib in an ALK-positive non-small cell lung cancer patient with brain metastases: A case report.
Ontology highlight
ABSTRACT: Rationale
The treatment of non-small cell lung cancer (NSCLC) has now changed dramatically in recent years and anaplastic lymphoma receptor tyrosine kinase (ALK) inhibitors are developing rapidly.Patient concerns
Here we reported a 57-year-old ALK-positive NSCLC man with brain metastases.Diagnoses
A case of lung adenocarcinoma with brain metastases.Interventions
Crizotinib was administered orally at a dose of 250mg twice a day until the brain metastases were found. Treatment with orally administered ceritinib at a dose of 450mg/d was initiated after crizotinib treatment.Outcomes
The patient is currently receiving maintenance ceritinib treatment, with no evidence of extracranial or intracranial tumor progression for 25 months.Lessons
Ceritinib may be a good choice for ALK-positive NSCLC patients with brain metastases who acquire resistance to crizotinib.
SUBMITTER: Zhu Z
PROVIDER: S-EPMC5690796 | biostudies-literature | 2017 Nov
REPOSITORIES: biostudies-literature
Publications
Crizotinib resistance overcome by ceritinib in an ALK-positive non-small cell lung cancer patient with brain metastases: A case report.
Medicine 20171101 45
<h4>Rationale</h4>The treatment of non-small cell lung cancer (NSCLC) has now changed dramatically in recent years and anaplastic lymphoma receptor tyrosine kinase (ALK) inhibitors are developing rapidly.<h4>Patient concerns</h4>Here we reported a 57-year-old ALK-positive NSCLC man with brain metastases.<h4>Diagnoses</h4>A case of lung adenocarcinoma with brain metastases.<h4>Interventions</h4>Crizotinib was administered orally at a dose of 250mg twice a day until the brain metastases were found ...[more]